宝济药业-B今日盘中大涨5.02%，引起了市场的广泛关注。
消息面上，此次股价上涨主要受到两大利好因素的推动。首先，公司董事会主席兼控股股东刘彦君博士宣布，计划在三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举向市场释放了控股股东对公司长期价值坚定认可的积极信号。其次，公司的新产品注射用人玻璃酸酶已获得国家药监局批准上市，这为公司产品管线增添了重要的商业化品种，显著增强了市场对公司未来盈利能力的预期。
此外，公司的股份购回授权也已获得股东大会通过，公司表示相关资金合法合规且不影响正常运营。控股股东的增持意愿与核心新产品的成功获批形成合力，共同提振了市场信心，推动了股价的强势表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.